Fetal hemoglobin (HbF) is the major genetic modulator of the hematologic and clinical
features of sickle cell disease, an effect mediated by its exclusion from the sickle hemoglobin …

The sickle hemoglobin (HbS) point mutation has independently undergone evolutionary
selection at least five times in the world because of its overwhelming malarial protective …

In the new edition of this successful and authoritative book, the thalassaemias are reviewed
in detail with respect to their clinical features, cellular pathology, molecular genetics …

The clinical course of patients with sickle cell anemia, a Mendelian trait, is characteristically
highly variable. HbF concentration and the presence of a thalassemia are established …

Identification of the molecular basis of the β‐thalassaemias and sickle cell disease (SCD)
has made it clear that patients with the same β‐globin genotypes can have very variable …

Sickle hemoglobin (HbS), caused by a point mutation in the β-globin gene of hemoglobin,
polymerizes when deoxygenated. The pathophysiology of sickle cell disease results from …

Aim: To report on molecular mechanisms of fetal hemoglobin (HbF) induction by
hydroxyurea (HU) for the treatment of sickle cell disease. Study Design: Systematic review …

Sickle cell disease is caused by a mutation in the β-globin chain of the haemoglobin
molecule. Sickle haemoglobin, the result of this mutation, has the singular property of …

The β‐thalassaemias have a major global impact on health and mortality. Allogeneic
haemopoietic stem cell transplantation is the only approach that may lead to a cure but this …

Fetal hemoglobin (HbF), the predominant hemoglobin in the fetus, is a mixture of two
molecular species (α2Gγ2 and α2Aγ2) that differ only at position 136 reflecting the products …